Maria Glymour, SD
Chair and Professor, Epidemiology - Boston University School of Public Health
Biography
Research Interests
- Alzheimer's disease and related causes of cognitive aging and dementia
- Modifiable determinants of dementia, including medications, behaviors, and socioeconomic position
- Health equity
- Social policies and health
- Causal inference in social epidemiology and dementia research
- Mentoring for excellence in public health
My research focuses on how social factors experienced across the lifecourse, from infancy to adulthood, influence cognitive function, dementia, stroke, and other health outcomes in old age. I am especially interested in education and other exposures amenable to policy interventions. The health of current cohorts of elderly individuals in the US reflect a lifetime of social exposures, including educational experiences shaped by major changes in schooling policies. Education is especially interesting because it is such a powerful predictor of health and historically, access to education has frequently been restricted based on race, gender, and other socially enforced criteria. One thread of my research examines how changes in schooling laws and school quality in the 20th century might have influenced the health and cognitive outcomes of current cohorts of elderly, including adults subject to race-based school segregation. Our results suggest that extra schooling has substantial benefits for memory function in the elderly. I have also worked on the influence of "place" on health, for example to understand the excess stroke burden for individuals who grew up in the US Stroke Belt. In a project with colleagues including Drs. Rachel Whitmer, Elizabeth Rose Mayeda, and Paola Gilsanz, we are continuing a unique multi-ethnic cohort of older adults in Northern California, with a wealth of lifecourse biological and social data to offer insight into the reasons for racial/ethnic differences in Alzheimer's and dementia risk (https://rachelwhitmer.ucdavis.edu/khandle).
A separate theme of my research focuses on overcoming methodological problems encountered in analyses of social determinants of health, Alzheimer's disease, and dementia. For many reasons, research focusing on lifecourse epidemiology as well as cognitive aging introduces substantial methodological challenges. Sometimes, these are conceptual challenges, and clear causal thinking can help! Many of these challenges are being addressed in the MELODEM (MEthods in LOngitudinal research on DEMentia) initiative, an international group of researchers focusing on analytic challenges in research on dementia and cognitive aging. MELODEM has working group phone calls on the first and third Thursdays of the month, open to all (https://sites.bu.edu/melodem/). My group works with numerous colleagues on methods to improve measurement, including crosswalking across data sets. For example, in work with Dr. Zeki Al Hazzouri, we are linking data sets with detailed information at different lifecourse periods -- e.g., childhood, early adulthood, and later adulthood -- to better evaluate long-term effects of exposures at specific sensitive ages. In work with Dr. Cathy Schaefer, Ron Krauss, and many others, we are fielding emulated trial designs in the large, diverse Kaiser Permanente Northern California cohort. This setting is exceptional for emulated trial designs because of the large size, long follow-up, and combination of high-quality clinical data plus social and genetic information for large groups of study participants.
I have advocated the use of causal directed acyclic graphs (DAGs) as a standard research tool to represent our causal hypotheses and help elucidate potential biases in proposed analyses. In other cases, the methodological problems require more analytical solutions that have been developed elsewhere in epidemiology or in other disciplines, but are rarely applied to these research questions. Instrumental variables analyses of natural or induced experiments are one promising example. Genetic variations have recently been advanced as possible instrumental variables to estimate the health effects of a wide range of phenotypes, an approach sometimes called “Mendelian Randomization.” Using genetic polymorphisms as instrumental variables could provide a very powerful tool for social epidemiology, but the inferences from such analyses rest on strong assumptions. Thus I am currently working with a team to explore approaches to evaluating the plausibility of those assumptions in applications for social epidemiology.
Students and post-doctoral fellows interested in research collaborations related to my work are welcome to send me an email directly or contact Marta Flores, mdflores@bu.edu, who handles my calendar. Feel free to reach out about the Epi Excellence (E2) Fellows or the Fellowship for Public Health Leveraging AI Responsibly (PHLAIR).
Education
- Harvard School of Public Health, SD Field of Study: Epidemiology
- Harvard School of Public Health, SM/ScM Field of Study: Epidemiology
- University of Chicago, AB Field of Study: Biology
Websites
Classes Taught
- SPHEP912
Publications
- Published on 6/3/2026
Ferguson EL, Miramontes S, White JS, Possin KL, Chodos A, Xia F, Raphael E, Smith AK, Glymour MM. Referral of patients with cognitive impairment to specialty memory care: associations with patient-centered outcomes and specificity of diagnoses. Am J Epidemiol. 2026 Jun 03; 195(6):1739-1748. PMID: 41766682.
Read At: PubMed
- Published on 6/1/2026
Colbeth HL, Roscoe JN, Corrada MM, Meunier CC, George KM, Glymour MM, Gilsanz P, Whitmer RA. Midlife hypertension and late-life cognition: weighting the LifeAfter90 study. Alzheimers Dement. 2026 Jun; 22(6):e71544. PMID: 42252490.
Read At: PubMed
- Published on 5/20/2026
Miramontes S, Ferguson EL, Zimmerman S, Phelps E, Oskotsky B, Oskotsky TT, Capra JA, Tsoy E, Sirota M, Glymour MM. Social and Cardiovascular Risk Factors as Predictors of the Progression from Mild Cognitive Impairment to Dementia in a Large EHR Database. medRxiv. 2026 May 20. PMID: 41822695.
Read At: PubMed
- Published on 5/8/2026
Khadka A, Pacca L, Hebert J, White JS, Hamad R, Brenowitz WD, Glymour MM, Vable AM. Impact of Vietnam-era G.I. Bill eligibility on the distribution of later-life memory score levels and decline: evidence from the Vietnam draft lottery natural experiment. Am J Epidemiol. 2026 May 08. PMID: 42101221.
Read At: PubMed
- Published on 5/7/2026
Keller JN, Kantor JA, Taveras C, Glymour MM, Fuster V, Elahi FM. Plasma Neurofilament Light Chain and Incident Cardiovascular Outcomes in the General Population. medRxiv. 2026 May 07. PMID: 42145642.
Read At: PubMed
- Published on 4/11/2026
Lozada-Tequeanes AL, Reimer CJ, Chivardi M, Miranda-Zuñiga JA, Miranda NB, Flesaker M, Glymour MM, Jiménez MP. Residential greenness and depressive symptoms in the Mexican adult population: A cross-sectional study. Prev Med Rep. 2026 Jun; 66:103467. PMID: 42016504.
Read At: PubMed
- Published on 4/7/2026
Lynch KM, Bennett EE, Liu C, Stapp EK, Levine DA, Glymour MM, Zimmerman SC, Griswold ME, Odden MC, Lopez OL, Power MC. Development and validation of a 2-step shared parameter model for dementia imputation in the Cardiovascular Health Study cohort. J Gerontol A Biol Sci Med Sci. 2026 Apr 07; 81(5). PMID: 41830439.
Read At: PubMed
- Published on 4/1/2026
Kieny C, Marks G, Bourgeois M, Alladi S, Atshan S, Brayne C, Dow W, Glymour M, Knapp D, Livingston G, Mahmud M, Monnet N, Papanicolas I, Platt E, Rehkopf D, Sadana R, Wallace L, Walsh S, Wenner M, Avendano M. The policy exposome of dementia: Gaps, opportunities, and research agenda. Alzheimers Dement. 2026 Apr; 22(4):e71362. PMID: 41979011.
Read At: PubMed
- Published on 4/1/2026
Roger JM, Costello J, Young H, Malave-Mendez TI, Miao BY, Brindis CD, Meckstroth K, Hernandez RD, Whetstone S, Raymond-Flesch M, Capra JA, Glymour MM, Torgerson D. Use of Paracervical Blocks for Patients Who Undergo Intrauterine Device Insertion. JAMA Netw Open. 2026 Apr 01; 9(4):e268406. PMID: 42012827.
Read At: PubMed
- Published on 3/26/2026
Kezios KL, Zimmerman SC, Buto PT, Glymour M, Zeki Al Hazzouri A. Income Volatility During Early to Mid-adulthood and 10-year Memory Decline in a Longitudinal Synthetic Cohort. Epidemiology. 2026 Jul 01; 37(4):532-543. PMID: 41885325.
Read At: PubMed
View 552 more publications:View Full Profile at BUMC
News & In the Media
- Published on June 4, 2026
- Published on April 2, 2026
-
Published on March 20, 2026
New Estimates of Uncounted COVID-19 Deaths Reveal Critical Gaps in US Death Investigation System
-
Published on March 13, 2026
Hackathon for Health Equity Sparks Student Interest in Epidemiology
- Published on November 21, 2025
-
Published on September 28, 2025
I’m Against Medical Research Cuts. We Need Those Answers for Our Health
-
Published on July 17, 2025
Texas Flood Should Not Have Happened. What Went Wrong? | Opinion
-
Published on June 14, 2025
Rise in Mortality Rates Linked to Heart Disease and Diabetes Among Less Educated Americans
-
Published on June 12, 2025
Congress Is Moving Backward on Funding for Alzheimer’s Disease Research | Opinion
- Published on February 15, 2025
- Published on January 9, 2025
- Published on December 13, 2024
-
Published on December 7, 2024
A Caregiving Chasm: Professor Reflects on the Shortcomings of the US Healthcare System
-
Published on November 13, 2024
Public Health Master’s Degrees in Epidemiology: What Questions to Ask
- Published on October 11, 2024
-
Published on October 8, 2024
Innovative Approaches to Prevent Dementia Funded by $28.8 Million Federal Grant
-
Published on September 27, 2024
Professor Receives $29M NIH Grant to Study Dementia Risk Factors, Prevention, and Treatment
-
Published on April 12, 2024
Depression May Lead to Faster Cognitive Decline among Black, Latino Adults
- Published on November 9, 2023
-
Published on October 6, 2023
Both High and Low HDL Cholesterol Tied to Increased Risk of Dementia
- Published on October 5, 2023
-
Published on September 8, 2023
After 2020 Increase, Excess Mortality among People with Dementia Drops in Year 2 of COVID
- Published on August 31, 2023
-
Published on July 10, 2023
FDA Gives Full Approval for New Alzheimer’s Drug, but Will It Help Black Patients?
-
Published on July 7, 2023
Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
-
Published on July 6, 2023
Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients